Clinical Roundup Phase III NATALEE trial: Kisqali demonstrates risk of recurrence in early breast cancer October 27, 2023Vol.49 No.40
Clinical Roundup Phase III PSMAfore trial: Pluvicto demonstrates clinically meaningful rPFS benefit in prostate cancer October 27, 2023Vol.49 No.40
Clinical Roundup Phase III ALINA study: Alecensa reduces risk of disease recurrence/death in NSCLC October 27, 2023Vol.49 No.40
Clinical Roundup UTSW: Emergency room visits by cancer patients can often be avoided October 27, 2023Vol.49 No.40
Clinical Roundup NCI-designated subspecialist reviews improve 94% of pancreatic cancer treatment paths October 27, 2023Vol.49 No.40
Clinical Roundup UC Davis researchers identify “switch” to activate cancer cell death October 27, 2023Vol.49 No.40
Clinical Roundup SWOG: Major pathologic response to neoadjuvant Keytruda in advanced melanoma trial exceeds 50% October 27, 2023Vol.49 No.40
Clinical Roundup Taletrectinib shrinks tumors in NSCLC indication in phase II trial October 27, 2023Vol.49 No.40
Clinical Roundup Longitudinal nucleocapsid antibody testing reveals undocumented SARS-CoV-2 infections in patients with lung cancer October 27, 2023Vol.49 No.40
Clinical Roundup PFAS forever chemicals could be a risk factor in thyroid cancer, Mount Sinai researchers find October 27, 2023Vol.49 No.40
